CryptoDex: a randomised, double-blind, placebo-controlled phase III trial of adjunctive dexamethasone in HIV-infected adults with cryptococcal meningitis: study protocol for a randomised control trial.

Journal article

BACKGROUND: Cryptococcal meningitis (CM) is a severe AIDS-defining illness with 90-day case mortality as high as 70% in sub-Saharan Africa, despite treatment. It is the leading cause of death in HIV patients in Asia and Africa.No major advance has been made in the treatment of CM since the 1970s. The mainstays of induction therapy are amphotericin B and flucytosine, but these are often poorly available where the disease burden is highest. Adjunctive treatments, such as dexamethasone, have had...

Expand abstract

Authors: Day, N; Imran, D; Ganiem, A; Tjahjani, N; Wahyuningsih, R

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: BioMed Central
• Journal: Trials
• Volume: 15
• Issue: 1
• Pages: 441
• Publication date: 2014-01-01
• DOI: 10.1186/1745-6215-15-441
• EISSN: 1745-6215
• ISSN: 1745-6215
• Language: English
• Keywords: Malawi; Asia; Dexamethasone; Double-Blind Method; Anti-Inflammatory Agents; Drug Therapy, Combination; Uganda; Meningitis, Cryptococcal; HIV Infections; AIDS-Related Opportunistic Infections; Antifungal Agents; Treatment Outcome; Clinical Protocols; Time Factors; Humans; Research Design